Could a pill that blocks estrogen help fight rare uterine cancers?

NCT ID NCT07467772

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing elacestrant, a pill that breaks down estrogen receptors, in 30 people with advanced uterine sarcomas that are fueled by estrogen. The goal is to see if the drug can shrink tumors or slow their growth. Participants must have tumors that strongly express estrogen receptors and cannot be treated with surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elacestrant (a drug that breaks down estrogen receptors, taken as a pill)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced uterine sarcomas that rely on estrogen to grow.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL STROMAL SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrioid stromal sarcoma estrogen-receptor positive breast cancer leiomyosarcoma of the corpus uteri neoplasm with perivascular epithelioid cell differentiation uterine corpus adenosarcoma uterine corpus leiomyoma uterine corpus perivascular epithelioid cell tumor uterine corpus sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL STROMAL SARCOMA ESS ESTROGEN RECEPTOR POSITIVE TUMOR PERIVASCULAR EPITHELIOID CELL TUMORS ULMS UTERINE ADENOSARCOMA UTERINE LEIOMYOSARCOMA UTERINE PECOMA UTERINE SARCOMA

Contacts and locations

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.